Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.

Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...

6 days ago · Novo plans to begin a new trial of CagriSema in the first half of 2025 which will be longer than the original 68-week study because the data suggested additional weight loss could be achieved with ...

Sep 11, 2024 · Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential...

Jan 27, 2025 · Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the...

Jan 28, 2025 · Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the course of 36 weeks.

Sep 10, 2024 · A daily weight loss pill from Novo Nordisk was shown to lower body weight by up to 13% after three months in a Phase 1 clinical trial, according to new findings.

Jan 17, 2025 · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest Eli Lilly’s rival GLP-1 drug Zepbound may still have an edge over Wegovy.